NEW YORK (GenomeWeb) – BioMarker Strategies has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute to develop a companion diagnostic to identify head and neck squamous cell carcinoma (HNSCC) patients most likely to benefit from Erbitux (cetuximab).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.